Executive Chairman

Executives

Dr Stephen Hodges, Founder and Executive Chairman, member of Management and Scientific Boards: is a Senior Fellow at The Royal Veterinary College and visiting Professor of Clinical Pharmacology at Tromsø University Hospital who discovered NaQuinate/Osteopura and has expertise derived from several academic environments working with established pharmaceutical companies, biotech companies and University-based drug and intellectual property development companies. Stephen trained as a chemist, bio-chemist, pharmacologist, cell biologist and has a background in analytical techniques, use of animal models through to co-running Phase I and II clinical trials; which ideally places him to oversee the early phase developments of Osteopura. Stephen has published over 70 peer reviewed papers.

Chief Executive Officer

Executives

Michael Sitton, Chief Executive Officer, Chair of Management Board: is a pharmacologist who has considerable experience in developing synthetic and biotech derived new drugs from inception to market launch. Michael has worked almost exclusively in the commercial sector of drug development, working for major drug companies and the biotechnology sector; his early career started with the in vitro and in vivo screening of novel compounds for their pharmacological and toxicological effects. After a spell as Head of General Toxicology, he later became the General Manager of a Contract Research Phase I Unit offering the full range of human volunteer studies from First in Man, to specialist subgroups. His responsibilities included the management of the Unit and its fiscal success. He moved on to patient studies and became Project Director for a number of global Phase II/III clinical trials, in a range of disease areas over a 10 year period. It was during this time he worked with the MHRA on inspection readiness procedures and spent some time as Liaison Officer working with the US National Cancer Institute and the FDA on Artificial Sweeteners. Michael most recently spent his time running Pharmacovigilence and Post Marketing Studies for a major pharma; thus taking him through the full range of drug development, from the very early biological screening to monitoring drugs that have been approved for use.

Chief Financial Officer

Executives

Ms. Carmen Greco, Founder and Chief Financial Officer, member of Management Board: has 22 years of global investment banking experience at the world’s leading financial institutions. She spent over fifteen years at Goldman Sachs as a Managing Director in New York and London and two years as a Managing Director at UBS in London. She has created and built up five separate businesses within the two organizations. Her teams focused on creating, developing and distributing both developed & emerging market risk management products to High Net Worth individuals, Institutions and Hedge fund clients around the world. Her considerable management skills, financial knowledge, regulatory, branding & marketing experience, combined with her client contacts will be invaluable for the company. Carmen will work most closely on a day to day basis with Dr. Stephen Hodges, Mr. Mike Sitton, Dr Robin Soper and Mr. Cenk Oguz.

Chief Scientific Officer

Executives

Dr Robin Soper, Founder and Chief Scientific Officer, Member of Management Board and Chair of Scientific Board: is a Senior Research Fellow with the Cancer Research UK Clinical Centre and has worked directly on the early development, from chemical synthesis through to testing the in vitro biological activity of NaQuinate, leading to the successful in vivo demonstration of NaQuinate as a protective agent of bone loss in two mouse models (Appendix I). Robin has also shown that NaQuinate has a limited adverse toxicity profile in the rodent. Robin will supervise and co-ordinate laboratory developments and make presentations to learned societies at appropriate points.

Chief Medical Officer

Executives

Mr Cenk Oguz, Founder and Chief Medical Officer, member of Management and Scientific Board: Currently working as a Consultant at The North London Hospitals NHS Trust. He is considered a rising force in the orthopaedic surgery community and will be conducting the research in close co-operation with Dr Soper in order to secure the information that will lead to successful application to the MHRA for the human Phase I clinical trial. Cenk will work in close consultation with Professor Emery at St. Mary’s Hospital London to ensure that the clinical trials are correctly completed and, importantly, he will make presentations to learned medical society meetings and conferences.

Scientist

Executives

Professor Andrew Pitsillides, Scientist, member of Scientific Board: is a Professor in The Royal Veterinary College who has an established academic career, marked as a ‘rising star’ of skeletal disease and skeletal development with over 90 prominent publications in highly reputable journals. The successful in vivo prosecution of the murine models of osteoporosis demonstrating the therapeutic potential of NaQuinate was overseen by Prof Pitsillides and Dr Hodges. Andrew will retain academic position and continue to add value on the efficacy animal testing and mechanism of action investigation.

Clinical Consultant

Executives

Professor Roger Emery, Director, Clinical Consultant, member of Scientific Board: Professor Emery studied medicine at St. Thomas's Hospital Medical School, London and trained in London, Cambridge and Hong Kong. He was awarded a Wellcome Surgical Fellowship at the Kennedy Institute of Rheumatology and wrote his master's thesis on "Metabolic Studies on Normal and Osteoporotic Bone". He was awarded the Zimmer Travelling Fellowship by the British Orthopaedic Association in 1989 and the first SECEC/ ASES Travelling Fellowship by the European Society for Surgery of the Shoulder and Elbow in 1993. In 1991, he was appointed consultant orthopaedic surgeon and honorary Senior Lecturer at the Central Middlesex Hospital and moved to St Mary's Hospital in 1993. He currently sits on the International Board of Shoulder and Elbow Surgery as an ex-officio member. His research interests focus on Osteoporosis and the effect of loading on bone cells in collaboration with the Royal Veterinary College, London

Scientific Consultant to Haoma Medica

Dr Martin Shearer, Scientific Consultant to Haoma Medica: Dr Martin Shearer is a Consultant Clinical Scientist at St Thomas’ Hospital. He is an internationally recognized expert in the field of vitamins, particularly in relation to the role of vitamin K in human health and disease and the development of analytical methods for the evaluation of vitamin K status. Martin is the recipient of research grants & contracts from prestigious academic & government institutions including the Medical Research Council, UK Food Standards Agency; UK Department of Health, US FDA, and US National Institute of Health and the UK National Osteoporosis Society. Since 1988 he has served on several National/International Expert Committees and Working Groups including those convened by the World Health Organization, the Food & Agriculture Organization of the UN, UK Department of Health, and UK MHRA. Martin is author/co-author of over 150 peer-reviewed scientific articles, book chapters and has edited a book on vitamin K.

Scientific Consultant to Haoma Medica

Professor Tim Arnett, Scientific Consultant to Haoma Medica: Tim Arnett is Professor of Mineralised Tissue Biology at University College London (UCL).   He is known internationally for his research in osteoclast and osteoblast biology, as well as for his widely reproduced bone images.   Professor Arnett has authored many publications and received research grants from industry, the MRC, BBSRC, Arthritis Research UK, Wellcome Trust and the European Union. He currently serves on the editorial boards of several journals, is secretary of the European Calcified Tissue Society and president-elect of the Bone Research Society. Tim Arnett has over 60 publications in bone biology.

Clinical Consultant to Haoma Medica

Professor Alan Boyde, Clinical Consultant to Haoma Medica: Professor Alan Boyde began his career with a degree in dentistry, so it was somewhat natural to find himself interested in hard tissue biology and in particular bone. With 44 years research experience in the Dept of Anatomy, University College London (over half as Professor) his depth of experience in the understanding of the dynamics of bone biology is considerable. Currently as Professor of Biophysics, Oral Growth and Development, Barts and The London, Queen Mary he continues to bring a unique insight into bone biology. Alan Boyde has over 200 publications in bone biology.